Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Somatostatin regulates amyloid beta peptide metabolism
July 25th, 2005
Endogenous somatostatin prevents the production of a key peptide mediator of Alzheimer disease-related neurodegeneration. "Expression of somatostatin in the brain declines during aging in various mammals, including apes and humans," neuroscientists in Japan explained. "A prominent decrease in this neuropeptide also represents a pathological characteristic of Alzheimer disease." "Using in vitro and in vivo paradigms," T. Saito and colleagues at the RIKEN Brain Science Institute discovered that "somatostatin regulates the metabolism of amyloid beta peptide (Abeta), the primary pathogenic agent of Alzheimer disease, in the brain through modulating...
Source: Health & Medicine Week (2005-07-25)
|
